Literature DB >> 22156354

Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.

Suzanna Ndraha1.   

Abstract

AIM: to evaluate the efficacy of combination of PPI with prokinetic drug compared to PPI mono therapy in GERD patients with high frequency scale for the symptoms of GERD (FSSG) score.
METHODS: sixty dyspeptic patients having heartburn and/or regurgitation were recruited during the period of July 2010-April 2011 in this double blind clinical trial. By randomization, they were divided into two groups; group A was given omeprazole 2 x 20 mg and domperidone 3 x 10 mg for 2 weeks, while another group was only given omeprazole 2 x 20 mg. The FSSG score was performed before treatment and after 2 weeks of treatment.
RESULTS: there were 20 (33%) males and 40 (67%) females. The mean total score of FSSG was 25.3 ± 8.2 at pretest, and 19.3 ± 9.7 at posttest, with improvement of 6.1 ± 4.9. The FSSG score in group A after treatment (19.3 ± 11.3) was significantly lower than before treatment (26.7 ± 8.9, p<0.001) as well as in group B (from 23.9 ± 7.3 to 19,3 ± 7.9, p<0.001). The mean improvement score in group A was 7.5 ± 5.9, while in the group B was of 4.6 ± 3.3, and this difference was statistically significant (p=0.02)
CONCLUSION: combination of omeprazole with domperidone in GERD patients with high FSSG score is more superior compared to omeprazole monotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156354

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  8 in total

Review 1.  Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.

Authors:  Li-Hua Ren; Wei-Xu Chen; Li-Juan Qian; Shuo Li; Min Gu; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.

Authors:  L Hillman; R Yadlapati; A J Thuluvath; M A Berendsen; J E Pandolfino
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

3.  Gastroesophageal reflux in patients treated for congenital diaphragmatic hernia: short- and long-term evaluation with multichannel intraluminal impedance.

Authors:  Anna Maria Caruso; Maria Rita Di Pace; Pieralba Catalano; Fabiana Farina; Alessandra Casuccio; Marcello Cimador; Enrico De Grazia
Journal:  Pediatr Surg Int       Date:  2013-04-10       Impact factor: 1.827

4.  Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease.

Authors:  K Y Marakhouski; G A Karaseva; D N Ulasivich; Y Kh Marakhouski
Journal:  Clin Med Insights Gastroenterol       Date:  2017-05-31

5.  A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.

Authors:  Da Hyun Jung; Cheal Wung Huh; Sang Kil Lee; Jun Chul Park; Sung Kwan Shin; Yong Chan Lee
Journal:  J Neurogastroenterol Motil       Date:  2021-04-30       Impact factor: 4.924

6.  A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease.

Authors:  Ju Yup Lee; Sung Kook Kim; Kwang Bum Cho; Kyung Sik Park; Joong Goo Kwon; Jin Tae Jung; Eun Young Kim; Byung Ik Jang; Si Hyung Lee
Journal:  J Neurogastroenterol Motil       Date:  2017-04-30       Impact factor: 4.924

Review 7.  Esophageal Motor Dysfunctions in Gastroesophageal Reflux Disease and Therapeutic Perspectives.

Authors:  Sihui Lin; Hua Li; Xiucai Fang
Journal:  J Neurogastroenterol Motil       Date:  2019-10-30       Impact factor: 4.924

8.  The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis.

Authors:  Liting Xi; Jinzhou Zhu; Huixian Zhang; Merlin Muktiali; Youming Li; Airong Wu
Journal:  Esophagus       Date:  2020-06-10       Impact factor: 4.230

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.